Hepatitis
Hepatitis 02/09/2010
Abbott receives FDA approval for first automated molecular test for assessing hepatitis B treatment
The assay is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy.
Hepatitis 02/09/2010
Inhibitex successfully completes Phase 1a trial of INX-189
Proof-of-concept trial in patients with chronic hepatitis C planned for Q4 2010.
Hepatitis 31/08/2010
Genetic factor strongly predicts response to hep C therapy
Testing for the gene could help identify those most—and least—likely to benefit from HCV treatment.
Hepatitis 30/08/2010
HCV protease inhibitors likely to work for co-infected patients previously treated for HCV
“Our results indicate that the potential efficacy of HCV PIs will be unaffected by previous HCV treatment in coinfected patients.”
Hepatitis 26/08/2010
ZymoGenetics announces completion of enrollment in Phase 2b clinical trial with PEG-interferon lambda in hepatitis C
The Phase 2 EMERGE study is an international, randomized multi-center clinical trial with PEG-Interferon lambda and ribavirin in treatment-naïve patients with HCV.
Hepatitis 25/08/2010
Pharmasset initiates Phase 2b clinical trial of PSI-7977 for chronic hepatitis C genotypes 1, 2, and 3
Phase 2b response-guided study in patients with genotype 1 HCV to receive PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon and ribavirin; Genotype 2 and 3 patients will be enrolled in an open label arm investigating 12 weeks of PSI-7977 400mg QD plus pegylated interferon and ribavirin; Interim Phase 2b data expected in first half of 2011.
Hepatitis 23/08/2010
Hepatitis E vaccine successful in clinical trial: study
The trial vaccine, codenamed HEV 239, is a recombinant vaccine, meaning that it includes a protein from the virus designed to stimulate the body's immune defenses.
Hepatitis 21/08/2010
Acute hepatitis C as a sexually transmitted infection in HIV positive men
Sexual transmission of hepatitis C virus among HIV positive men who have sex with men has now been recognized for a decade, occurring in cities in Europe, North America, and Australia. Since acute HCV outbreaks occur almost exclusively among men with HIV, being HIV positive probably plays a critical role.
Hepatitis 18/08/2010
Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients
Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis.
Hepatitis 14/08/2010
Boost for drugs against hepatitis C
Promising clinical trial results point to the pharmaceutical industry's next blockbuster.
Hepatitis 13/08/2010
PSI-7977 receives fast track designation from the FDA for the treatment of chronic hepatitis C infection
PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV.
Hepatitis 11/08/2010
Phase 3 ILLUMINATE study supports 24-week telaprevir-based therapy within a response-guided regimen for people with hepatitis C who had not received prior treatment
Viral cure rates of 92% and 88% with 24 and 48-week regimens, respectively, in people who met certain response criteria; Safety and tolerability results were similar to those seen in the Phase 3 ADVANCE study.
Hepatitis 11/08/2010
Chronic hepatitis C infection blunts CD4 gains after start of HIV treatment
Ongoing hepatitis C replication inhibits improvements in the CD4 cell counts of HIV-positive patients taking antiretroviral therapy.
Hepatitis 09/08/2010
Hepatitis drug prices may drop as much as 40%
Getz Pharma launches a drug for the treatment of hepatitis in Pakistan and its manufacturing will be 40 per cent cheaper than imports.
Hepatitis 09/08/2010
Tattoos increase risk of hepatitis C
A systematic review and meta-analysis of 124 published studies from 30 countries, found that people with tattoos were almost three times more likely to have hepatitis C as those without tattoos.
Hepatitis 09/08/2010
Adverse effects of HCV therapy more common in HIV-infected women
Physicians should be aware that HIV-infected women have a greater chance of developing side effects overall during interferon-based and ribavirin HCV therapy and antiretroviral regimens during therapy may play a role in the development of these side effects.
Hepatitis 06/08/2010
OraSure delays filing for oral version of hep C test
Says filing for oral version of HCV test delayed; Says FDA commented on lower sensitivity of tests.
Hepatitis 04/08/2010
Hepatitis B linked to lymphoma in study
People infected with hepatitis B virus are around twice as likely to develop non-Hodgkin lymphoma, researchers reported on Tuesday.
Hepatitis 04/08/2010
Two pivotal Phase III registration studies for boceprevir completed and meet the primary endpoints
In pivotal Phase III studies boceprevir helped majority of patients with chronic hepatitis C genotype 1 infection achieve SVR, the primary endpoint of the studies; Merck expects to submit NDA by year-end.
Hepatitis 29/07/2010
Vertex has begun telaprevir FDA application
Rolling telaprevir FDA application underway.
More...
